Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which has completed Phase 1 clinical stage for neuropathic pain conditions; SAN903 for inflammatory and fibrotic disorders; and SAN2219, that is in preclinical stage for treatment of epilepsy. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS; and research collaboration with AstronauTx to identify new treatments for Alzheimer’s disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.